small nucleolar RNA, C/D box 37Genealiases: RNU37 · U37
Q-omics provides the consensus-scored SNORD37 profile across patient tissues and cancer cell-line models. SNORD37 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SNORD37 is differentially expressed in 2, with the highest sampling consensus in KIRP. Additionally, SNORD37 RNA expression shows 11,042 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, and TGCT as cancer lineages where SNORD37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD37 survival associations across molecular data types. SNORD37 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD37 RNA expression–survival associations across cancer types. High SNORD37 expression shows unfavorable associations in KIRP, MESO, BLCA, ESCA, DLBC and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SNORD37 RNA expression.
This table summarizes SNORD37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD37 shows higher tumor expression in KIRP and PRAD. The KIRP box plot shows higher SNORD37 RNA expression in tumor versus normal tissue (log2 FC = +0.334, t-test p = .012).
This table shows molecular features associated with SNORD37 in patient tissues and cancer cell lines. In patient samples, SNORD37 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
